Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-017439
Filing Date
2022-08-15
Accepted
2022-08-15 17:54:26
Documents
98
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q lhdx-20220630.htm   iXBRL 10-Q 3745892
2 EX-10.1 lhdx-ex10_1.htm EX-10.1 81267
3 EX-31.1 lhdx-ex31_1.htm EX-31.1 30524
4 EX-31.2 lhdx-ex31_2.htm EX-31.2 30635
5 EX-32.1 lhdx-ex32_1.htm EX-32.1 13747
6 EX-32.2 lhdx-ex32_2.htm EX-32.2 11985
  Complete submission text file 0000950170-22-017439.txt   13276314

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lhdx-20220630.xsd EX-101.SCH 75019
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lhdx-20220630_def.xml EX-101.DEF 251797
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lhdx-20220630_lab.xml EX-101.LAB 575691
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT lhdx-20220630_cal.xml EX-101.CAL 57441
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lhdx-20220630_pre.xml EX-101.PRE 466001
92 EXTRACTED XBRL INSTANCE DOCUMENT lhdx-20220630_htm.xml XML 2602572
Mailing Address 1412 62ND STREET EMERYVILLE CA 94608
Business Address 1412 62ND STREET EMERYVILLE CA 94608 (814) 574-1546
Lucira Health, Inc. (Filer) CIK: 0001652724 (see all company filings)

EIN.: 272491037 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39976 | Film No.: 221167252
SIC: 2835 In Vitro & In Vivo Diagnostic Substances